| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiratory Hypersensitivity | 7 | 2019 | 103 | 2.43 | Why? |
| Helicobacter pylori | 4 | 2019 | 262 | 1.88 | Why? |
| Asthma | 14 | 2021 | 4383 | 1.81 | Why? |
| Pulmonary Disease, Chronic Obstructive | 10 | 2018 | 3832 | 1.55 | Why? |
| Circadian Rhythm | 4 | 2018 | 607 | 1.44 | Why? |
| Helicobacter Infections | 3 | 2019 | 216 | 1.36 | Why? |
| Allergens | 7 | 2019 | 728 | 1.24 | Why? |
| Goblet Cells | 4 | 2019 | 181 | 1.10 | Why? |
| Bronchodilator Agents | 2 | 2017 | 444 | 0.92 | Why? |
| Lung Transplantation | 6 | 2020 | 1554 | 0.79 | Why? |
| Wnt1 Protein | 2 | 2018 | 7 | 0.77 | Why? |
| Hypersensitivity | 3 | 2019 | 1137 | 0.70 | Why? |
| Bronchitis | 1 | 2019 | 146 | 0.68 | Why? |
| Pulmonary Medicine | 2 | 2021 | 706 | 0.67 | Why? |
| Tiotropium Bromide | 1 | 2017 | 46 | 0.67 | Why? |
| Benzoxazines | 1 | 2017 | 103 | 0.67 | Why? |
| Antigens, Bacterial | 1 | 2019 | 330 | 0.62 | Why? |
| Bronchial Hyperreactivity | 3 | 2011 | 38 | 0.59 | Why? |
| Omalizumab | 1 | 2017 | 158 | 0.59 | Why? |
| Exercise Tolerance | 2 | 2019 | 634 | 0.57 | Why? |
| Pyroglyphidae | 3 | 2019 | 52 | 0.55 | Why? |
| beta Catenin | 1 | 2014 | 78 | 0.54 | Why? |
| Exercise | 4 | 2018 | 6771 | 0.50 | Why? |
| Forced Expiratory Volume | 5 | 2019 | 632 | 0.50 | Why? |
| Ovalbumin | 6 | 2019 | 84 | 0.48 | Why? |
| Anti-Asthmatic Agents | 1 | 2017 | 427 | 0.48 | Why? |
| Immunoglobulin E | 4 | 2019 | 557 | 0.48 | Why? |
| Lung | 15 | 2020 | 31049 | 0.48 | Why? |
| Self-Management | 1 | 2018 | 546 | 0.47 | Why? |
| Nitric Oxide | 2 | 2018 | 769 | 0.45 | Why? |
| Th2 Cells | 4 | 2019 | 680 | 0.44 | Why? |
| T-Lymphocytes, Regulatory | 3 | 2018 | 698 | 0.42 | Why? |
| Sputum | 1 | 2019 | 1720 | 0.42 | Why? |
| Th1 Cells | 2 | 2018 | 1228 | 0.39 | Why? |
| Dendritic Cells | 4 | 2019 | 1330 | 0.37 | Why? |
| Mice, Inbred C57BL | 10 | 2019 | 5542 | 0.36 | Why? |
| Patient Care Management | 1 | 2018 | 1514 | 0.33 | Why? |
| Respiratory Function Tests | 3 | 2020 | 1755 | 0.33 | Why? |
| Software | 1 | 2018 | 2501 | 0.32 | Why? |
| Immunocompromised Host | 2 | 2020 | 5150 | 0.31 | Why? |
| Netherlands | 4 | 2018 | 3533 | 0.30 | Why? |
| Smoke | 3 | 2018 | 349 | 0.29 | Why? |
| T-Lymphocytes | 6 | 2019 | 6670 | 0.29 | Why? |
| Tobacco Products | 2 | 2018 | 245 | 0.27 | Why? |
| Signal Transduction | 3 | 2018 | 7207 | 0.27 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.27 | Why? |
| Mice | 12 | 2019 | 21357 | 0.26 | Why? |
| Disease Models, Animal | 8 | 2019 | 10998 | 0.24 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.24 | Why? |
| Coculture Techniques | 2 | 2014 | 258 | 0.23 | Why? |
| Epithelial Cells | 4 | 2018 | 3508 | 0.23 | Why? |
| Inflammation | 9 | 2019 | 13255 | 0.23 | Why? |
| Germany | 6 | 2021 | 9196 | 0.22 | Why? |
| Linear Models | 2 | 2017 | 1914 | 0.21 | Why? |
| Mast Cells | 2 | 2019 | 370 | 0.21 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.20 | Why? |
| Cells, Cultured | 7 | 2018 | 5835 | 0.20 | Why? |
| Biopsy | 2 | 2019 | 2811 | 0.20 | Why? |
| Histological Techniques | 1 | 2019 | 35 | 0.20 | Why? |
| Aminophenols | 1 | 2019 | 22 | 0.20 | Why? |
| Austria | 2 | 2021 | 1259 | 0.20 | Why? |
| Interleukin-13 | 2 | 2018 | 204 | 0.19 | Why? |
| Citrobacter rodentium | 1 | 2018 | 11 | 0.19 | Why? |
| Ovum | 1 | 2018 | 35 | 0.19 | Why? |
| Wnt-5a Protein | 1 | 2018 | 14 | 0.19 | Why? |
| Bronchoalveolar Lavage Fluid | 3 | 2018 | 2309 | 0.19 | Why? |
| Vital Capacity | 2 | 2018 | 399 | 0.19 | Why? |
| Schistosoma mansoni | 1 | 2018 | 27 | 0.19 | Why? |
| Hyperplasia | 1 | 2019 | 204 | 0.19 | Why? |
| Cystic Fibrosis | 2 | 2019 | 1104 | 0.19 | Why? |
| Twins, Monozygotic | 1 | 2019 | 83 | 0.19 | Why? |
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2019 | 113 | 0.18 | Why? |
| Bronchiolitis Obliterans | 1 | 2018 | 86 | 0.18 | Why? |
| Mediastinal Neoplasms | 1 | 2019 | 57 | 0.18 | Why? |
| Antibodies, Protozoan | 1 | 2018 | 121 | 0.18 | Why? |
| Wnt Signaling Pathway | 1 | 2018 | 87 | 0.18 | Why? |
| Virus Activation | 2 | 2019 | 480 | 0.17 | Why? |
| Respiratory Tract Infections | 1 | 2019 | 6817 | 0.17 | Why? |
| Obesity | 2 | 2018 | 7388 | 0.17 | Why? |
| Interleukin-7 | 1 | 2018 | 148 | 0.17 | Why? |
| Quinolones | 1 | 2019 | 167 | 0.17 | Why? |
| Actigraphy | 1 | 2017 | 102 | 0.17 | Why? |
| Flow Cytometry | 2 | 2017 | 2393 | 0.16 | Why? |
| Cytomegalovirus | 2 | 2019 | 600 | 0.16 | Why? |
| Animals | 19 | 2019 | 78931 | 0.16 | Why? |
| Female | 32 | 2021 | 380317 | 0.16 | Why? |
| Extracorporeal Circulation | 1 | 2018 | 130 | 0.16 | Why? |
| Cell Differentiation | 3 | 2018 | 1338 | 0.16 | Why? |
| Accelerometry | 1 | 2018 | 228 | 0.16 | Why? |
| Genetic Predisposition to Disease | 2 | 2021 | 4027 | 0.16 | Why? |
| Trachea | 2 | 2018 | 894 | 0.15 | Why? |
| Disease Progression | 5 | 2018 | 13580 | 0.15 | Why? |
| Mice, Inbred BALB C | 5 | 2018 | 5814 | 0.15 | Why? |
| Mucin-1 | 1 | 2018 | 277 | 0.15 | Why? |
| Self Report | 2 | 2018 | 3802 | 0.15 | Why? |
| Mice, Transgenic | 2 | 2014 | 2739 | 0.15 | Why? |
| Sleep Apnea Syndromes | 1 | 2019 | 282 | 0.14 | Why? |
| Lithium Chloride | 1 | 2014 | 14 | 0.14 | Why? |
| Transcriptome | 2 | 2019 | 3466 | 0.14 | Why? |
| Humans | 44 | 2021 | 930598 | 0.14 | Why? |
| Decision Support Techniques | 2 | 2020 | 903 | 0.14 | Why? |
| Acute Disease | 3 | 2019 | 6029 | 0.14 | Why? |
| Prenatal Exposure Delayed Effects | 1 | 2018 | 319 | 0.14 | Why? |
| Immunophenotyping | 1 | 2019 | 1290 | 0.14 | Why? |
| Bronchi | 2 | 2018 | 1048 | 0.13 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.13 | Why? |
| Spirometry | 1 | 2017 | 524 | 0.13 | Why? |
| Lymphoma | 1 | 2019 | 522 | 0.13 | Why? |
| Cell Culture Techniques | 1 | 2018 | 704 | 0.13 | Why? |
| Antigens, Neoplasm | 1 | 2015 | 230 | 0.13 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.13 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.13 | Why? |
| RNA-Binding Proteins | 1 | 2021 | 1022 | 0.13 | Why? |
| Receptors, IgE | 2 | 2019 | 26 | 0.12 | Why? |
| Transplant Recipients | 2 | 2020 | 4982 | 0.12 | Why? |
| Cytomegalovirus Infections | 1 | 2019 | 667 | 0.12 | Why? |
| Disease Susceptibility | 2 | 2020 | 4002 | 0.12 | Why? |
| Respiratory Tract Diseases | 1 | 2020 | 1061 | 0.12 | Why? |
| Cross-Sectional Studies | 7 | 2021 | 53120 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.11 | Why? |
| Common Cold | 1 | 2018 | 645 | 0.11 | Why? |
| Eosinophils | 1 | 2018 | 848 | 0.11 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.11 | Why? |
| Doxycycline | 1 | 2014 | 307 | 0.11 | Why? |
| Interleukin-9 | 1 | 2010 | 29 | 0.11 | Why? |
| Risk Reduction Behavior | 1 | 2018 | 946 | 0.11 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2021 | 3607 | 0.11 | Why? |
| Cytokines | 6 | 2019 | 15010 | 0.11 | Why? |
| Aged | 16 | 2021 | 215776 | 0.10 | Why? |
| Computer-Assisted Instruction | 1 | 2018 | 658 | 0.10 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.10 | Why? |
| Cell Movement | 1 | 2014 | 695 | 0.10 | Why? |
| Gastrointestinal Tract | 1 | 2018 | 1113 | 0.10 | Why? |
| Male | 22 | 2021 | 367725 | 0.10 | Why? |
| Lung Diseases | 2 | 2020 | 2361 | 0.10 | Why? |
| Interferon Regulatory Factors | 1 | 2010 | 141 | 0.10 | Why? |
| Long-Term Care | 1 | 2021 | 2047 | 0.10 | Why? |
| Mice, Knockout | 2 | 2011 | 1815 | 0.09 | Why? |
| Biomarkers | 4 | 2019 | 23361 | 0.09 | Why? |
| Environmental Exposure | 1 | 2019 | 1558 | 0.09 | Why? |
| Heart Ventricles | 1 | 2017 | 1139 | 0.09 | Why? |
| Adenocarcinoma | 1 | 2015 | 651 | 0.09 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.09 | Why? |
| Graft Rejection | 1 | 2018 | 1766 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Preoperative Care | 1 | 2017 | 1515 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2019 | 3788 | 0.08 | Why? |
| Bariatric Surgery | 1 | 2017 | 1298 | 0.08 | Why? |
| Obesity, Morbid | 1 | 2017 | 1340 | 0.08 | Why? |
| Carbocysteine | 1 | 2005 | 4 | 0.08 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 497 | 0.08 | Why? |
| Wounds and Injuries | 1 | 2019 | 1708 | 0.08 | Why? |
| Radiography, Thoracic | 2 | 2020 | 5486 | 0.08 | Why? |
| Adult | 15 | 2021 | 244371 | 0.08 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.08 | Why? |
| Pyrrolidonecarboxylic Acid | 1 | 2004 | 4 | 0.08 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Predictive Value of Tests | 2 | 2018 | 9537 | 0.07 | Why? |
| Fear | 1 | 2021 | 3607 | 0.07 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.07 | Why? |
| Respiratory System | 1 | 2018 | 3213 | 0.07 | Why? |
| Calcitonin Gene-Related Peptide | 1 | 2004 | 52 | 0.07 | Why? |
| Health Promotion | 1 | 2018 | 2020 | 0.07 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.07 | Why? |
| Adjuvants, Immunologic | 1 | 2014 | 1709 | 0.07 | Why? |
| Symptom Assessment | 1 | 2018 | 4967 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2020 | 17020 | 0.07 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.07 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.07 | Why? |
| Time Factors | 2 | 2017 | 31397 | 0.06 | Why? |
| Echocardiography | 1 | 2017 | 3661 | 0.06 | Why? |
| Tuberculosis, Lymph Node | 1 | 2002 | 27 | 0.06 | Why? |
| Health Behavior | 1 | 2021 | 4449 | 0.06 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Immunity, Innate | 3 | 2018 | 6570 | 0.05 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Pandemics | 4 | 2020 | 389249 | 0.05 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.05 | Why? |
| CD11 Antigens | 1 | 2019 | 74 | 0.05 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.05 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2002 | 260 | 0.05 | Why? |
| Chymases | 1 | 2019 | 86 | 0.05 | Why? |
| Budesonide | 1 | 2021 | 192 | 0.05 | Why? |
| Lymphocyte Activation | 2 | 2019 | 2742 | 0.05 | Why? |
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 75 | 0.05 | Why? |
| Thoracic Surgery, Video-Assisted | 1 | 2019 | 97 | 0.05 | Why? |
| Organ Preservation | 1 | 2018 | 49 | 0.04 | Why? |
| Heterozygote | 1 | 2019 | 249 | 0.04 | Why? |
| Toll-Like Receptor 2 | 1 | 2019 | 198 | 0.04 | Why? |
| Immunoglobulin G | 2 | 2019 | 21571 | 0.04 | Why? |
| Cell Degranulation | 1 | 2018 | 130 | 0.04 | Why? |
| Lung Neoplasms | 1 | 2015 | 3228 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 8811 | 0.04 | Why? |
| Alum Compounds | 1 | 2018 | 210 | 0.04 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.04 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2004 | 846 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2019 | 264 | 0.04 | Why? |
| Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 234 | 0.04 | Why? |
| Diet Therapy | 1 | 2017 | 66 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Perfusion | 1 | 2018 | 254 | 0.04 | Why? |
| Cilia | 1 | 2018 | 183 | 0.04 | Why? |
| Polysomnography | 1 | 2019 | 296 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2019 | 10083 | 0.04 | Why? |
| Microscopy, Confocal | 1 | 2018 | 343 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.04 | Why? |
| Antigen Presentation | 1 | 2019 | 524 | 0.04 | Why? |
| B7-H1 Antigen | 1 | 2019 | 541 | 0.04 | Why? |
| Multimorbidity | 1 | 2021 | 703 | 0.04 | Why? |
| Child | 3 | 2018 | 70012 | 0.04 | Why? |
| Receptors, Immunologic | 1 | 2019 | 555 | 0.04 | Why? |
| Eosinophilia | 1 | 2018 | 292 | 0.04 | Why? |
| Colitis | 1 | 2018 | 266 | 0.04 | Why? |
| Allografts | 1 | 2018 | 761 | 0.04 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2004 | 1234 | 0.04 | Why? |
| Body Mass Index | 2 | 2018 | 4306 | 0.04 | Why? |
| Desensitization, Immunologic | 1 | 2020 | 574 | 0.04 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.04 | Why? |
| Immunity, Mucosal | 1 | 2018 | 426 | 0.04 | Why? |
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 130 | 0.04 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.03 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.03 | Why? |
| Exhalation | 1 | 2018 | 441 | 0.03 | Why? |
| In Vitro Techniques | 1 | 2017 | 1027 | 0.03 | Why? |
| Immune Tolerance | 1 | 2018 | 608 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.03 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.03 | Why? |
| Th17 Cells | 1 | 2018 | 657 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Safety | 1 | 2021 | 1583 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Workflow | 1 | 2020 | 2373 | 0.03 | Why? |
| Antibody Specificity | 1 | 2015 | 1328 | 0.03 | Why? |
| Molecular Sequence Data | 1 | 2015 | 3198 | 0.02 | Why? |
| Genotype | 1 | 2021 | 4697 | 0.02 | Why? |
| Extracellular Traps | 1 | 2018 | 1036 | 0.02 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.02 | Why? |
| Prostaglandins E | 1 | 1988 | 7 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Linoleic Acids | 1 | 1988 | 51 | 0.02 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.02 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Interferon-gamma | 1 | 2018 | 2711 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.02 | Why? |
| Dietary Fats | 1 | 1988 | 96 | 0.02 | Why? |
| Telemedicine | 1 | 2018 | 25032 | 0.02 | Why? |
| Promoter Regions, Genetic | 1 | 2010 | 823 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Anti-Inflammatory Agents | 1 | 2005 | 6153 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2018 | 3567 | 0.02 | Why? |
| Neurokinin-1 Receptor Antagonists | 1 | 2004 | 9 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| RNA, Small Interfering | 1 | 2010 | 817 | 0.02 | Why? |
| Bone and Bones | 1 | 1988 | 235 | 0.02 | Why? |
| Substance P | 1 | 2004 | 23 | 0.02 | Why? |
| Glucocorticoids | 1 | 2021 | 4431 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2017 | 2585 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Antiemetics | 1 | 2004 | 75 | 0.02 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2015 | 6049 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Tuberculin Test | 1 | 2002 | 141 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Biopsy, Needle | 1 | 2002 | 303 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| Bacteriological Techniques | 1 | 2002 | 239 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Mutation | 1 | 2019 | 12376 | 0.01 | Why? |
| Air Pollution | 1 | 2017 | 3504 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Antitubercular Agents | 1 | 2002 | 775 | 0.01 | Why? |
| Lymph Nodes | 1 | 2002 | 1060 | 0.01 | Why? |
| Anxiety | 1 | 2021 | 17311 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Peptide Fragments | 1 | 2004 | 2075 | 0.01 | Why? |
| Protein Binding | 1 | 2010 | 11430 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.01 | Why? |
| Rats, Inbred Strains | 1 | 1988 | 14 | 0.01 | Why? |
| Cobalt | 1 | 1968 | 33 | 0.01 | Why? |
| Linoleic Acid | 1 | 1988 | 65 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2002 | 7268 | 0.01 | Why? |
| Femur | 1 | 1988 | 100 | 0.01 | Why? |
| Lumbar Vertebrae | 1 | 1988 | 196 | 0.00 | Why? |
| Blood Coagulation Factors | 1 | 1968 | 223 | 0.00 | Why? |
| Reference Values | 1 | 1988 | 795 | 0.00 | Why? |
| Rats | 1 | 1988 | 2764 | 0.00 | Why? |
| Blood Coagulation | 1 | 1968 | 2768 | 0.00 | Why? |
| Calcium Chloride | 1 | 1968 | 4 | 0.00 | Why? |
| Glutamates | 1 | 1968 | 12 | 0.00 | Why? |
| Injections, Intraperitoneal | 1 | 1968 | 69 | 0.00 | Why? |
| Blood Viscosity | 1 | 1968 | 71 | 0.00 | Why? |
| Fibrin | 1 | 1968 | 145 | 0.00 | Why? |
| Thrombin | 1 | 1968 | 325 | 0.00 | Why? |
| Rabbits | 1 | 1968 | 1171 | 0.00 | Why? |
| Polymers | 1 | 1968 | 507 | 0.00 | Why? |
| Blood Coagulation Tests | 1 | 1968 | 855 | 0.00 | Why? |
| Temperature | 1 | 1968 | 2305 | 0.00 | Why? |